Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of LIPO-5 and ALVAC-HIV (vCP1452) in Healthy Adults
NCT00076063Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2004
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LIPO-5 and ALVAC-HIV in human immunodeficiency virus infection (HIV) (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Immune response to vaccines and Clinical and laboratory adverse events. Started Mar 2004; status: completed.
02
Drugs
LIPO-5ALVAC-HIV
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00076063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076063.